When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ALTACE® should be discontinued as soon as possible. See WARNINGS: Fetal/neonatal morbidity and mortality.
Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes
Ramipril and ramiprilat inhibit angiotensin-converting enzyme (ACE).
Altace is indicated for the ollowing:
REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
Altace is indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Altace can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy).
ALTACE is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.
In using ALTACE, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ALTACE does not have a similar risk. (See WARNINGS.)
In considering use of ALTACE, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)
HEART FAILURE POST MYOCARDIAL INFARCTION
Ramipril is indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure Post Myocardial Infarction for details and limitations of the survival trial.)
Published Studies Related to Altace (Ramipril)
Potential vascular mechanisms of ramipril induced increases in walking ability in
patients with intermittent claudication. 
CONCLUSIONS: Ramipril is associated with an increase in the biomarkers of
Effect of naproxen and acetaminophen on blood pressure lowering by ramipril,
valsartan and aliskiren in hypertensive patients. 
CONCLUSIONS: Both naproxen and acetaminophen can affect anti-hypertensive therapy
Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril,
in patients with intermittent claudication. 
parameters in patients with peripheral arterial disease... CONCLUSION: Ramipril improved walking distance in patients with claudication;
Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary
regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention Of
the deleterious effects of Pulmonary Regurgitation In Adults with repaired
TEtralogy of Fallot). 
ramipril and its effects on cardiovascular function in these patients... CONCLUSIONS: Ramipril is a well tolerated therapy, improves biventricular
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. [2011.07.01]
CONCLUSIONS: Our 3-month study in nondiabetic hypertensive patients showed a decrease in biomarkers of IR and chronic systemic inflammation with the PIO monotherapy and the PIRA combination only, which may help to explain some findings in other cardiovascular outcome trials. (c) 2011 Diabetes Technology Society.
Clinical Trials Related to Altace (Ramipril)
Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes [Terminated]
The purpose of this study is to determine if a dose of ramipril combined with a normal dose
of telmisartan 80 mg will be more effective than ramipril 20 mg in reducing microalbuminuria
in hypertensive patients with diabetes.
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's [Recruiting]
Angiotensin converting enzyme inhibitors (ACE-I) are a group of blood pressure-lowering
medicines. Some studies suggest that ACE-I, such as ramipril, may help prevent Alzheimer's
disease (AD). The purpose of the research is to see how ramipril affects a substance in the
body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the
brain and spinal cord. High amounts of beta-amyloid may be associated with a greater risk of
getting Alzheimer's disease. This study will see if ramipril can lower the amount of
beta-amyloid in the spinal fluid. This study will also see if ramipril affects blood vessel
function and memory and thinking. The investigators hope that future studies will show
whether ramipril might prevent memory loss and decrease the chance of developing Alzheimer's
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients [Recruiting]
This prospective multicenter, double blind study will evaluate the efficacy and safety of
aliskiren versus ramipril in patients with moderate systolic essential hypertension.
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Systolic Heart Failure [Recruiting]
In addition to the blood pressure lowering effects of aliskiren, it may have beneficial
effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue
level. An increase of angiotensin II is associated with worsening of heart failure.
Therefore the study will test the effects of ramipril, aliskiren and the combination of both
on levels on angiotensin II in the blood in patients with systolic heart failure.
A 54 Week, Randomized, Double-Blind, Parallel-Group, Multicenter Study Evaluating the Long-Term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension [Recruiting]
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren
(300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
Reports of Suspected Altace (Ramipril) Side Effects
Drug Interaction (46),
Renal Failure Acute (36),
Drug Ineffective (35),
Oedema Peripheral (21),
Palpitations (20), more >>
Page last updated: 2014-11-30